The animal experimental protocol was approved by the Institutional Animal Care and Use Committee, Chosun University, Gwangju, Korea (CIACUC2019-A0015). All experiments were performed in accordance with relevant guidelines and regulations. Five-week-old male athymic nude mice (BALB-c/nu, Orient Bio Co. LTD, Seoul, Korea) were used to generate a xenograft model by intracardiac injection of PC3 Wild , PC3 +RANKL (RANKL overexpression), or PC3 +RANKL + IM (immunisation) cells. Following immunisation, mice were divided into an immunisation group and a non-immunisation group. The Sham group was immunised by a subcutaneous injection of PBS, while the immunisation group was injected subcutaneously with mRANKL-MT (100 µg/kg three times every 2 weeks). Mouse sera and tissue samples were collected according to indicated schedule.
Balb c nu
Manufactured by Orient Bio
BALB-c/nu is a laboratory mouse strain used in research. It is a nude mouse, meaning it lacks a functional thymus gland and therefore has a compromised immune system. This strain is commonly used in research involving transplantation, oncology, and immunology.
Automatically generated - may contain errors
Lab products found in correlation
7 protocols using balb c nu
1
Xenograft model of prostate cancer
2
Generating Xenograft Model for Prostate Cancer
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The animal experimental protocol was approved by the Institutional Animal Care and Use Committee, Chosun University, Gwangju, Korea (CIACUC2019-A0015). The study was carried out in compliance with the ARRIVE guidelines. All experiments were performed in accordance with relevant guidelines and regulations. Five-week-old male athymic nude mice (BALB-c/nu, Orient Bio Co. LTD, Seoul, Korea) were used to generate a xenograft model by intracardiac injection of PC3Wild, PC3+RANKL (RANKL overexpression), or PC3+RANKL + IM (immunisation) cells. Following immunisation, mice were divided into an immunisation group and a non-immunisation group. The Sham group was immunised by a subcutaneous injection of PBS, while the immunisation group was injected subcutaneously with mRANKL-MT (100 μg/kg three times every 2 weeks). Mouse sera and tissue samples were collected according to the indicated schedule.
3
Docetaxel-Loaded Hydrogel Delivery for Tumor Suppression
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
44As3Luc cells (1 × 106 cells per mouse) were intraperitoneally injected in six-week-old female athymic nude mice (Balb/c-nu; Orient Bio Inc., Seoul, Korea). The mice were randomly divided into six groups (The photon counts were no significantly differences between each group; Supplementary Figure 3A and 3B ), and treated as follows: 1) intraperitoneal (IP) injection of PBS (PBS group, n=10), 2) IP injection of hydrogel without docetaxel (hydrogel group, n=10), 3) intravenous (IV) injection of 2 mg/kg × 4 docetaxel solution without hydrogel (DTX-sol IV group, 2 times/week × 2, n=10), 4) IP injection of 2 mg/kg × 4 docetaxel solution without hydrogel (DTX-sol IP group, 2 times/week × 2, n=10), 5) IP injection of PPZ hydrogel physically mixed with 2 mg/kg docetaxel (low dose DTX-gel) 6) IP injection of PPZ hydrogel physically mixed with 8 mg/kg docetaxel (high dose DTX-gel) (Table 2 ). From three days after cell injection, these treatments were administered. On the 8, 14 and 28 days after treatment, one mouse of each group was randomly selected and sacrificed for gross and microscopic examination of intraperitoneal organs and suspicious tumor nodules. This animal study was approved by the IACUC of Seoul National University Hospital.
4
Aligned cell-hydrogel constructs enhance limb perfusion in hindlimb ischemia
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Hindlimb ischemia was induced in anesthetized athymic female mice (Balb/c-nu, 6 weeks old, Orient Bio)49 . After skin incision, the left iliac and femoral arteries were permanently ligated using a 6-0 prolene suture (Ethicon). Immediately after ligation of the arteries, 3D cell-hydrogel constructs, pre-matured in vitro for 1 week, were placed onto the defective muscle, fully covering the ischemic region. The mice were divided into four groups: (i) no-treatment, (ii) hydrogel-alone (Gel), (iii) randomly distributed cell-hydrogel construct (Random), and (iv) aligned cell-hydrogel construct (Align). The status of the lower extremity of the left limb on day 28 was evaluated to determine its physiological status score. Amputation of the lower extremity was designated as limb loss, and rotten skin and muscle of the left limb was designated as necrosis. The blood perfusion in ischemic hindlimbs was monitored by serial scanning using a laser Doppler imaging system (MoorLDI2-HIR High Resolution, Moor Instruments, Axminster, Devon, UK) on days 0, 2, 7, 14, 21, and 28 after treatment67 (link). Blood flow was quantified using digital color-coded images from the knee joint region to the toe region, and the perfusion rate was calculated as the ratio of ischemic limb to normal limb. Four weeks after transplantation, the mice were sacrificed for histological analysis.
5
Evaluating C-PC Efficacy in Murine Models
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The in vivo e cacy of C-PC was evaluated using female BALB/c-nu and female BALB/c mice (Orient Bio, Korea). The study was approved by the Institutional Animal Care and Use Committee of Inha University (Incheon in South Korea, Approval Number, INHA 150924-381). Animals were housed in a climatecontrolled environment (25 ± 2°C, 45% relative humidity) with a 12 h light/dark cycle and provided ad libitum access to food and water. The animals of each type were divided into seven groups (Table. 1). Each group has 3 animals and a total of 21 mouse of each species were used. BALB/c mice were depilated using a hair removal cream. For 12 days, 5% imiquimod cream was applied every morning to the dorsal skin of the mice. From the 7 th day, C-PC was administered to the remaining four groups(Group , Group , Group , Group ) similar to the positive control, once a day in the evening. The negative control group was treated with the buffer used to purify the C-PC and maintained as the induced disease control group. BALB/c-nu and BALB/c mice were euthanized on the 12 th day using CO2, and the skin, spleen, and ears were collected from each group.
6
Preclinical Animal Study Protocol
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
All animal experimental procedure complied with the ARRIVE (Animal Research: Reporting in Vivo Experiments) guidelines2.0 for preclinical animal studies and were approved by the Institutional Animal Care and Use Committee of Seoul National University Hospital (SNUH-IACUC 19-0135). All experiments were performed in accordance with relevant guidelines and regulations. C57BL/6N and BALB/c-nu mice were obtained from ORIENTBIO Inc, Korea. All animals housed in the specific-pathogen-free laboratory animal room at Seoul National University Hospital.
7
Immunisation against RANKL in Xenograft Model
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The animal experimental protocol was approved by the Institutional Animal Care and Use Committee, Chosun University, Gwangju, Korea (CIACUC2019-A0015). All experiments were performed in accordance with relevant guidelines and regulations. Five-week-old male athymic nude mice (BALB-c/nu, Orient Bio Co. LTD, Seoul, Korea) were used to generate a xenograft model by intracardiac injection of PC3 Wild , PC3 +RANKL (RANKL overexpression), or PC3 +RANKL + IM (immunisation) cells. Following immunisation, mice were divided into an immunisation group and a non-immunisation group. The Sham group was immunised by a subcutaneous injection of PBS, while the immunisation group was injected subcutaneously with mRANKL-MT (100 mg/kg three times every 2 weeks). Mouse sera and tissue samples were collected according to indicated schedule.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!